This table lists NICE published technology appraisals that have been transferred to the static list. Guidance is moved to the static list following consultation with consultees and commentators when it is clear that there is no new research available that would have any material effect on the current guidance. Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.


Ref Title Date Issued Review decision
TA1 Wisdom teeth - removal Mar 2000 Review decision
TA10 Asthma (children under 5) - inhaler devices Aug 2000 Review decision
TA20 Motor neurone disease - riluzole Jan 2001 Review decision
TA25 Pancreatic cancer - gemcitabine May 2001 Review decision
TA29 Leukaemia (lymphocytic) - fludarabine Sep 2001 Review decision
TA32 Multiple sclerosis - beta interferon and glatiramer acetate Jan 2002 Review decision
TA35 Arthritis (juvenile idiopathic) - etanercept Mar 2002 Review decision
TA38 Asthma (older children) - inhaler devices Mar 2002 Review decision
TA47 Acute coronary syndromes - glycoprotein IIb/IIIa inhibitors (review) Sep 2002 Review decision
TA48 Renal failure - home versus hospital haemodialysis Sep 2002 Review decision
TA49 Central venous catheters - ultrasound locating devices Sep 2002 Review decision
TA52 Myocardial infarction - thrombolysis Oct 2002 Review decision
TA53 Diabetes (types 1 and 2) - long acting insulin analogues Dec 2002 Review decision
TA55 Ovarian cancer - paclitaxel (review) Jan 2003 Review decision
TA59 Electroconvulsive therapy (ECT) Apr 2003 Review decision
TA60 Diabetes (types 1 and 2) - patient education models Apr 2003 Review decision
TA61 Colorectal cancer - capecitabine and tegafur uracil May 2003 Review decision
TA65 Non-Hodgkin's lymphoma - rituximab Sep 2003 Review decision
TA69 Cervical cancer - cervical screening (review) Oct 2003 Review decision
TA73 Angina and myocardial infarction - myocardial perfusion scintigraphy Nov 2003 Review decision
TA75 Hepatitis C - pegylated interferons, ribavirin and alfa interferon Jan 2004 Review decision
TA74 Trauma - fluid replacement therapy Jan 2004 Review decision
TA77 Insomnia - newer hypnotic drugs Apr 2004 Review decision
TA78 Menstrual bleeding - fluid-filled thermal balloon and microwave endometrial ablation Apr 2004 Review decision
TA80 Acute coronary syndromes - clopidogrel Jul 2004 Review decision
TA82 Atopic dermatitis (eczema) - pimecrolimus and tacrolimus Aug 2004 Review decision
TA81 Atopic dermatitis (eczema) - topical steroids Aug 2004 Review decision
TA83 Hernia - laparoscopic surgery (review) Sep 2004 Review decision
TA85 Renal transplantation - immuno-suppressive regimens (adults) Sep 2004 Review decision
TA86 Gastrointestinal stromal tumours - imatinib Oct 2004 Review decision
TA94 Cardiovascular disease - statins Jan 2006 Review decision
TA96 Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alfa-2a Feb 2006 Review decision
TA98 Attention deficit hyperactivity disorder (ADHD) - methylphenidate, atomoxetine and dexamfetamine (review) Mar 2006 Review decision
TA100 Colon cancer (adjuvant) - capecitabine and oxaliplatin Apr 2006 Review decision
TA101 Prostate cancer (hormone-refractory) - docetaxel Jun 2006 Review decision
TA105 Colorectal cancer - laparoscopic surgery (review) Aug 2006 Review decision
TA106 Hepatitis C - peginterferon alfa and ribavirin Aug 2006 Review decision
TA112 Breast cancer (early) - hormonal treatments Nov 2006 Review decision
TA115 Drug misuse - naltrexone Jan 2007 Review decision
TA114 Drug misuse - methadone and buprenorphine Jan 2007 Review decision
TA117 Hyperparathyroidism - cinacalcet Jan 2007 Review decision
TA116 Breast cancer - gemcitabine Jan 2007 Review decision
TA118 Colorectal cancer (metastatic) - bevacizumab and cetuximab Jan 2007 Review decision
TA119 Leukaemia (lymphocytic) - fludarabine Feb 2007 Review decision
TA165 Organ preservation (renal) - machine perfusion and static storage Nov 2008 Review decision
TA123 Smoking cessation - varenicline Jul 2007 Review decision
TA124 Lung cancer (non-small-cell) - pemetrexed Aug 2007 Review decision
TA129 Multiple myeloma - bortezomib Oct 2007 Review decision
TA131 Asthma (in children) - corticosteroids Nov 2007 Review decision
TA171 Multiple myeloma - lenalidomide Jun 2009 Review decision
TA135 Mesothelioma - pemetrexed disodium Jan 2008 Review decision
TA134 Psoriasis - infliximab Jan 2008 Review decision
TA137 Lymphoma (follicular non-Hodgkin's) - rituximab Feb 2008 Review decision
TA136 Structural neuroimaging in first-episode psychosis Feb 2008 Review decision
TA139 Sleep apnoea - continuous positive airway pressure (CPAP) Mar 2008 Review decision
TA138 Asthma (in adults) - corticosteroids Mar 2008 Review decision
TA143 Ankylosing spondylitis - adalimumab, etanercept and infliximab May 2008 Review decision
TA145 Head and neck cancer - cetuximab Jun 2008 Review decision
TA151 Diabetes - insulin pump therapy Jul 2008 Review decision
TA153 Hepatitis B - entecavir Aug 2008 Review decision
TA156 Pregnancy (rhesus negative women) - routine anti-D (review) Aug 2008 Review decision
TA154 Hepatitis B - telbivudine Aug 2008 Review decision
TA157 Venous thromboembolism - dabigatran Sep 2008 Review decision
TA158 Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir Sep 2008 Review decision
TA159 Pain (chronic neuropathic or ischaemic) - spinal cord stimulation Oct 2008 Review decision
TA164 Hyperuricaemia - febuxostat Dec 2008 Review decision
TA166 Hearing impairment - cochlear implants Jan 2009 Review decision
TA170 Venous thromboembolism - rivaroxaban Apr 2009 Review decision
TA169 Renal cell carcinoma - sunitinib Mar 2009 Review decision
TA172 Head and neck cancer (squamous cell carcinoma) - cetuximab Jun 2009 Review decision
TA173 Hepatitis B - tenofovir disoproxil fumarate Jul 2009 Review decision
TA176 Colorectal cancer (first line) - cetuximab Aug 2009 Review decision
TA177 Eczema (chronic) - alitretinoin Aug 2009 Review decision
TA178 Renal cell carcinoma Aug 2009 Review decision
TA179 Gastrointestinal stromal tumours - sunitinib Sep 2009 Review decision
TA183 Cervical cancer (recurrent) - topotecan Oct 2009 Review decision
TA184 Lung cancer (small-cell) - topotecan Nov 2009 Review decision
TA185 Soft tissue sarcoma - trabectedin Feb 2010 Review decision
TA187 Crohn's disease - infliximab (review) and adalimumab (review of TA40) May 2010 Review decision
TA189 Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line) May 2010 Review decision
TA188 Human growth hormone (somatropin) for the treatment of growth failure in children (review) May 2010 Review decision
TA191 Gastric cancer (advanced) - capecitabine Jul 2010 Review decision
TA195 Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor Aug 2010 Review decision
TA197 Atrial fibrillation - dronedarone Aug 2010 Review decision
TA200 Hepatitis C - peginterferon alfa and ribavirin Sep 2010 Review decision
TA208 Gastric cancer (HER2-positive metastatic) - trastuzumab Nov 2010 Review decision
TA209 Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib Nov 2010 Review decision
TA211 Constipation (women) - prucalopride Dec 2010 Review decision
TA210 Vascular disease - clopidogrel and dipyridamole Dec 2010 Review decision
TA212 Colorectal cancer (metastatic) - bevacizumab Dec 2010 Review decision
TA214 Breast cancer - bevacizumab (in combination with a taxane) Feb 2011 Review decision
TA215 Renal cell carcinoma (first line metastatic) - pazopanib Feb 2011 Review decision
TA225 Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab Jun 2011 Review decision
TA230 Myocardial infarction (persistent ST-segment elevation) - bivalirudin Jul 2011 Review decision
TA236 Acute coronary syndromes - ticagrelor Oct 2011 Review decision
TA235 Osteosarcoma - mifamurtide Oct 2011 Review decision
TA247 Rheumatoid arthritis - tocilizumab (rapid review TA198) Feb 2012 Review decision
TA249 Atrial fibrillation - dabigatran etexilate Mar 2012 Review decision
TA256 Atrial fibrillation (stroke prevention) - rivaroxaban May 2012 Review decision
TA275 Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban Feb 2013 Review decision